Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
48
RDY Quote, Financials, Valuation and Earnings
Last price:
$14.13
Seasonality move
:
4.79%
Day range:
$14.45 - $14.55
52-week range:
$12.26 - $16.17
Dividend yield:
0.66%
P/E ratio:
18.13x
P/S ratio:
2.97x
P/B ratio:
2.84x
Volume:
3.1M
Avg. volume:
2M
1-year change:
14.4%
Market cap:
$11.8B
Revenue:
$3.9B
EPS (TTM):
$0.78
Analysts' Opinion
-
Consensus RatingDr. Reddy's Laboratories Ltd. has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $14.32, Dr. Reddy's Laboratories Ltd. has an estimated upside of 1.37% from its current price of $14.54.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.40 representing 100% downside risk from its current price of $14.54.
Fair Value
-
According to the consensus of 5 analysts, Dr. Reddy's Laboratories Ltd. has 1.37% upside to fair value with a price target of $14.32 per share.
RDY vs. S&P 500
-
Over the past 5 trading days, Dr. Reddy's Laboratories Ltd. has underperformed the S&P 500 by -2.39% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Dr. Reddy's Laboratories Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Dr. Reddy's Laboratories Ltd. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Dr. Reddy's Laboratories Ltd. reported revenues of $979.5M.
Earnings Growth
-
Dr. Reddy's Laboratories Ltd. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Dr. Reddy's Laboratories Ltd. reported earnings per share of $0.16.
Enterprise value:
11.6B
EV / Invested capital:
2.36x
Price / LTM sales:
2.97x
EV / EBIT:
16.36x
EV / Revenue:
2.93x
PEG ratio (5yr expected):
13.41x
EV / Free cash flow:
129.02x
Price / Operating cash flow:
68.29x
Enterprise value / EBITDA:
12.40x
Gross Profit (TTM):
$2.2B
Return On Assets:
10.66%
Net Income Margin (TTM):
16.25%
Return On Equity:
15.8%
Return On Invested Capital:
13.68%
Operating Margin:
15.74%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $3.3B | $3.7B | $4B | $989.8M | $979.5M | |
| Gross Profit | $1.8B | $2.1B | $2.2B | $570.9M | $525.4M | |
| Operating Income | $733.6M | $796.7M | $711.5M | $206.5M | $154.2M | |
| EBITDA | $906.9M | -- | $938.1M | -- | $213.5M | |
| Diluted EPS | $0.76 | $0.77 | $0.78 | $0.20 | $0.16 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.2B | $2.4B | $2.9B | -- | $3.3B | |
| Total Assets | $3.8B | $3.7B | $4.5B | -- | $6.3B | |
| Current Liabilities | $1.1B | $1B | $1.1B | -- | $1.8B | |
| Total Liabilities | $1.2B | $1.1B | $1.3B | $1.9B | $2.1B | |
| Total Equity | $2.6B | $2.7B | $3.2B | -- | $4.2B | |
| Total Debt | $91.9M | $74.9M | $90.2M | $101.4M | $194.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $645.4M | $430.7M | -- | -- | $112.9M | |
| Cash From Investing | -$562.1M | -$669.1M | -- | -- | -$116.4M | |
| Cash From Financing | -$66.1M | $304.4M | -- | -- | $100.6M | |
| Free Cash Flow | $344.7M | $79.3M | -- | -- | $32.9M | |
RDY
Sector
Market Cap
$11.8B
$25.3M
Price % of 52-Week High
87.38%
48.74%
Dividend Yield
0.66%
0%
Shareholder Yield
0.34%
-1.64%
1-Year Price Total Return
11.52%
-19.12%
Beta (5-Year)
0.337
0.492
Dividend yield:
0.66%
Annualized payout:
$0.10
Payout ratio:
-11.82%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$14.38
200-day SMA
Buy
Level
$14.27
Bollinger Bands (100)
Buy
Level
13.54 - 14.4
Chaikin Money Flow
Buy
Level
64.9M
20-day SMA
Buy
Level
$14.42
Relative Strength Index (RSI14)
Buy
Level
60.19
ADX Line
Buy
Level
11.52
Williams %R
Buy
Level
-82.716
50-day SMA
Buy
Level
$13.95
MACD (12, 26)
Buy
Level
0.13
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
179.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.9378)
Buy
CA Score
(Annual)
Level (1.4438)
Sell
Beneish M-Score
(Annual)
Level (-1.9899)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-2.8942)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
Stock Forecast FAQ
In the current month, RDY has received 2 Buy ratings 2 Hold ratings, and 1 Sell ratings. The RDY average analyst price target in the past 3 months is $14.32.
-
Where Will Dr. Reddy's Laboratories Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Dr. Reddy's Laboratories Ltd. share price will rise to $14.32 per share over the next 12 months.
-
What Do Analysts Say About Dr. Reddy's Laboratories Ltd.?
Analysts are divided on their view about Dr. Reddy's Laboratories Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Dr. Reddy's Laboratories Ltd. is a Sell and believe this share price will drop from its current level to $11.40.
-
What Is Dr. Reddy's Laboratories Ltd.'s Price Target?
The price target for Dr. Reddy's Laboratories Ltd. over the next 1-year time period is forecast to be $14.32 according to 5 Wall Street analysts, 2 of them rate the stock a Buy, 1 rates the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is RDY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Dr. Reddy's Laboratories Ltd. is a Leans Bullish. 2 of 5 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of RDY?
You can purchase shares of Dr. Reddy's Laboratories Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Dr. Reddy's Laboratories Ltd. shares.
-
What Is The Dr. Reddy's Laboratories Ltd. Share Price Today?
Dr. Reddy's Laboratories Ltd. was last trading at $14.13 per share. This represents the most recent stock quote for Dr. Reddy's Laboratories Ltd.. Yesterday, Dr. Reddy's Laboratories Ltd. closed at $14.54 per share.
-
How To Buy Dr. Reddy's Laboratories Ltd. Stock Online?
In order to purchase Dr. Reddy's Laboratories Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get RDY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RDY
Sector
P/E ratio
18.13x
21.47x
PEG ratio
13.41x
-0.01x
P/B ratio
2.84x
1.74x
Price / LTM sales
2.97x
1.45x
Growth Metrics
RDY
Sector
Revenue growth
-1.04%
3.36%
Earnings growth
-18.89%
11.93%
Revenue (5-year growth)
9.35%
6.25%
Earnings forecast
$0.19
-$0.20
Profitability
RDY
Sector
Profitability FY 2024
$2.1B
$2.2M
Return on invested capital
13.68%
-33.31%
Return on assets
10.66%
-29.82%
Return on equity
15.8%
-40.01%
Earnings Date
Last Earnings Date
Jan
21
Next Earnings Date
May
7
Estimated Next Earnings Date
Apr
22
Balance Sheet
RDY
Sector
Total cash
$918.9M
$24.9M
Short term investments
$505.7M
$23.2M
Total assets
$5.8B
$69.8M
Long term debt
$194.1M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
92
APEI alert for Mar 13
American Public Education, Inc. [APEI] is up 26.24% over the past day.
Buy
52
PZZA alert for Mar 13
Papa John's International, Inc. [PZZA] is down 5.25% over the past day.
Buy
53
NBIS alert for Mar 13
Nebius Group NV [NBIS] is up 0.87% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
